Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Sézary_syndrome
|
| gptkbp:affects |
T-lymphocytes
|
| gptkbp:age |
gptkb:Person
adults |
| gptkbp:associated_with |
gptkb:HIV/_AIDS
gptkb:Down_syndrome autoimmune disorders |
| gptkbp:caused_by |
malignant T-cells
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:end_of_life |
varies by type
improving with treatment |
| gptkbp:events |
supportive care
regular check-ups monitoring for relapse |
| gptkbp:genetic_diversity |
NOTC H1 mutations
T P53 mutations CDK N2 A deletions |
| gptkbp:historical_context |
advancements in treatment in 2000s
first described in 1950s increased research in 1980s |
| https://www.w3.org/2000/01/rdf-schema#label |
T-cell leukemia
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:research_focus |
gptkb:vaccine
clinical trials targeted therapy |
| gptkbp:risk_factor |
genetic mutations
viral infections exposure to radiation |
| gptkbp:social_responsibility |
blood tests
bone marrow biopsy depends on subtype depends on age depends on overall health |
| gptkbp:symptoms |
fatigue
weight loss fever nutritional support pain relief night sweats psychosocial support enlarged lymph nodes |
| gptkbp:treatment |
radiation therapy
chemotherapy corticosteroids relapse remission stem cell transplant antineoplastic agents targeted drugs |
| gptkbp:type |
acute T-cell leukemia
chronic T-cell leukemia |